Compelling Data in Breast Cancer Treatment with First-In-Class Cyclin A/B Inhibitor Presented at 2023 AACR-NCI-EORTC International Conference Epsilon09242023-10-23T08:17:12-07:00October 23, 2023|Press Releases|
Circle Pharma Announces Upcoming Presentation at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Epsilon09242023-10-09T10:22:51-07:00October 9, 2023|Press Releases|
Circle Pharma strengthens its executive leadership team with two senior appointments in Clinical Development Epsilon09242023-07-26T12:30:16-07:00July 26, 2023|Press Releases|
Circle Pharma Achieves Major Milestone with the Selection of a Clinical Development Candidate Directly Inhibiting Cyclins A and B Epsilon09242023-07-19T10:25:55-07:00July 19, 2023|Press Releases|
Circle Pharma’s first-in-class orally bioavailable macrocyclic cyclin A/B inhibitors highlighted in poster presentations at American Association for Cancer Research Annual Meeting Epsilon09242023-07-19T07:02:31-07:00April 19, 2023|Press Releases|
Circle Pharma appoints Stephen Kelsey, MB ChB, MD, to its board of directors Epsilon09242023-07-19T07:03:44-07:00December 15, 2022|Press Releases|
Circle Pharma Appoints Paul Park, MBA, as its Chief Business Officer Epsilon09242023-07-19T07:04:10-07:00July 26, 2022|Press Releases|
Circle Pharma announces presentation at the American Association for Cancer Research 2022 Annual Meeting Epsilon09242023-07-19T07:04:36-07:00April 11, 2022|Press Releases|
Circle Pharma appoints Evelyn Wang, PhD as its Vice President, Translational Medicine Epsilon09242023-07-19T07:05:02-07:00July 12, 2021|Press Releases|
Circle Pharma raises $66 Million in Series C Financing Epsilon09242023-07-19T07:05:28-07:00June 16, 2021|Press Releases|
